ClinicalTrials.gg
RecruitingNCT07289776Updated Feb 20, 2026

A First-in-human Trial of GRT7041 in Healthy Participants

A Phase 1 interventional study of GRT7041 SAD and Placebo in Treatment of Pain, sponsored by Grünenthal GmbH. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Pain by Grünenthal GmbH — 1 open to participants now, 1 under way, none of them phase 3. Pain · Grünenthal GmbH.

Planned enrollment
14th of 19
70 · median 136
Started
2026
the only one that year
Phase 1
6 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Pain by Grünenthal GmbH, this one is the 14th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 1, and was the 19th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 19 studies in Pain by Grünenthal GmbH is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pain by Grünenthal GmbH, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants.

The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose [SAD]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose [MAD]), and the Treatment Period will be up to 14 days (for Part 2).

The trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit/End-of-Trial (EoT) Visit.

Read the detailed description

The trial will consist of two parts:

  • Part 1: SAD with up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and women of non-childbearing potential (WONCBP).
  • Part 2: MAD with up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.

The trial design also evaluate the potential interaction of GRT7041 with a CYP3A4 index substrate that will be assessed separately in all cohorts in Part 2 (MAD) of the trial.

Dosing in Parts 1 and 2 will be conducted under fasted conditions, except for the SAD3 cohort in Part 1 (SAD), where participants will also receive a standardized breakfast (SAD3b treatment) to assess the effect of food.

03

Conditions studied

  • Treatment of Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. The participant must be able to give signed , including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Participants must sign the ICF before any trial-related assessments.
  3. The participant is in good health as judged by the Investigator including medical history, physical examination, 12-lead , vital signs (pulse rate, respiratory rate, systolic and diastolic BP), body temperature, and clinical laboratory parameters (clinical chemistry, hematology, coagulation and urinalysis) without deviations from reference ranges, unless further specified in the exclusion criteria.

Main Exclusion Criteria:

  1. History of any of the following: cardiac impairment, renal impairment, pancreatitis, coagulation abnormalities.
  2. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk for treatment complications/ participation in the trial unsafe.
  3. Any disease or conditions known to interfere with the absorption, distribution, metabolism, or excretion of the IMP.
  4. Evidence or medical history of clinically significant and relevant psychiatric issues as assessed by the Investigator.
  5. Confirmed or suspected history of clinically relevant drug allergy.
  6. Major surgical procedure, within 30 days prior to ICF signing, or anticipation of need for a major surgical procedure during the trial.
  7. Blood loss of 500 mL or more (eg, owing to blood donation) within 90 days before Screening Visit.
  8. The participant has used any medication, including herbal remedies or over-the-counter medication within 2 weeks (or 5 half-lives, whichever is longer) before the start of the trial intervention or anticipated use during the trial, unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the trial.
  9. The participant is enrolled in another clinical trial unless it is an observational (non-interventional) clinical trial or during the follow-up period of an interventional trial) or has received an IMP in another clinical trial within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer.
  10. Reluctance to comply with requirements.
  11. Evidence or history of alcohol or drug abuse including positive or missing alcohol breath test or drugs of abuse test(s).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Part 1: SAD

    With up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and WONCBP

    Drug: GRT7041 SAD · Drug: Placebo

  • Experimental
    Part 2: MAD

    With up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.

    Drug: Placebo · Drug: Midazolam · Drug: GRT7041 MAD

Interventions

  • DrugGRT7041 SAD

    Single ascending doses

  • DrugPlacebo

    Placebo to match GRT7041 dose strength

  • Solution

  • DrugGRT7041 MAD

    Multiple ascending doses

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    An AE is defined as any unfavorable medical occurrence in a trial participant administered the investigational product. Assessment of the safety and tolerability of GRT7041 after oral single and multiple-dose escalation

    Time frame: Through study completion, an average of 8 Weeks

  2. Number of participants with Serious Adverse Events

    A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose: * Results in death, is life-threatening, or requires (or prolongs) hospitalization; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly or birth defect; or * Is considered medically significant, requiring intervention to prevent one of the outcomes above. * Investigator judgment applies to other clinically important events that may not be immediately life-threatening but could jeopardize participant safety. Assessment of the safety and tolerability of GRT7041 after oral single and multiple-dose escalation

    Time frame: Through study completion, an average of 8 Weeks

Secondary outcomes

  1. Area Under the Concentration-Time Curve from 0 to 24 hours [(AUC)0-24] [SAD]

    The total amount of the study drug (and metabolite) in the blood during the first 24 hours after it is taken. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  2. Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] [SAD]

    The total amount of the study drug (and metabolite) in the blood from the time it is taken until the last time a measurable level of the drug is found. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  3. Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) [SAD]

    The total amount of the study drug (and metabolite) in the blood from the time it is taken until it has completely left the body. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  4. Maximum Observed Plasma Concentration (Cmax) [SAD]

    The maximum amount of the study drug (and metabolite) measured in the blood after taking the dose. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax) [SAD]

    The time it takes to reach the highest concentration of the study drug (and metabolite) in the blood after dosing. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  6. Terminal Elimination Half-Life (t₁/₂) [SAD]

    The time it takes for the amount of study drug (and metabolite) in the blood to reduce by half after reaching its peak level. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  7. Terminal Elimination Rate Constant (λz) [SAD]

    The rate at which the study drug (and metabolite) is eliminated from the blood during the final phase after dosing. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  8. Apparent Total Clearance of Drug From Plasma After Extravascular Administration (CL/F) [SAD]

    The amount of blood completely cleared of thestudy drug (and metabolite) per unit of time, taking into account how much of the drug is absorbed into the body. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  9. Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) [SAD]

    An estimate of how widely the study drug spreads through the body's tissues after it is absorbed. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  10. Lag Time Before First Measurable Concentration (tlag) [SAD]

    The time between when the study drug (and metabolite) is taken and when it first becomes measurable in the blood. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  11. Time of Last Measurable Concentration (tlast) [SAD]

    The last time point when a measurable amount of the study drug (and metabolite) is found in the blood. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  12. Amount of Study Drug Excreted in Urine (Ae) [SAD]

    The total amount of the study drug (and metabolite) that is passed out of the body through urine during a specific collection period. Collected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (from 0 hours to 72 hours)

  13. Cumulative Amount of Study Drug Excreted in Urine (Cumulative Ae) [SAD]

    The total amount of the study drug (and metabolite) eliminated in urine from the time of dosing up to the end of each collection period, showing how much of the drug has been removed from the body over time. Collected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (from 0 hours to 72 hours)

  14. Percentage of Dose Excreted in Urine (Ae%) [SAD].

    The percentage of the total amount of the study drug (and metabolite) dose that is passed out in urine during each collection period. Collected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (from 0 hours to 72 hours)

  15. Cumulative Percentage of Dose Excreted in Urine (Cumulative Ae%) [SAD]

    The total percentage of the study drug dose excreted in urine from dosing until the end of each collection period, showing how much of the drug has been eliminated over time. Collected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (from 0 hours to 72 hours)

  16. Renal Clearance of Study Drug (CLr) [SAD]

    The rate at which the study drug (and metabolite) is removed from the blood by the kidneys and excreted in the urine. Collected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.

    Time frame: Day 1 to Day 4 (from 0 hours to 72 hours)

  17. Area Under the Concentration-Time Curve from 0 to 24 hours [(AUC)0-24] [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing.

    Time frame: Day 1 (0 hours - 24 hours)

  18. Maximum Observed Plasma Concentration (Cmax) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing.

    Time frame: Day 1 (0 hours - 24 hours)

  19. Time to Reach Maximum Observed Plasma Concentration (Tmax) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing.

    Time frame: Day 1 (0 hours - 24 hours)

  20. Area Under the Plasma Concentration-time Curve Over a Dose Interval at Steady State (AUCτ,ss) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 14 - Day 17 (0 hours to 72 hours after last dose) and Day 21

  21. Maximum Observed Plasma Concentration at Steady State (Cmax,ss) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 14 - Day 17 (0 hours to 72 hours after last dose) and Day 21

  22. Minimum Observed Plasma Concentration at Steady State (Cmin,ss) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  23. Average Observed Plasma Concentration at Steady State (Cav.ss) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  24. Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State (tmax,ss) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 14 - Day 17 (0 hours to 72 hours after last dose) and Day 21

  25. Terminal Elimination Half-Life (t₁/₂) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  26. Terminal Elimination Rate Constant (λz) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  27. Apparent Total Clearance of Drug From Plasma After Extravascular Administration (CL/F) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  28. Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21

  29. Time of Last Measurable Concentration (tlast) [MAD]

    Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing

    Time frame: Day 14 - Day 17 (0 hours to 72 hours after last dose) and Day 21

  30. Maximum Observed Plasma Concentration (Cmax) [SAD] for fed and fasted state

    Assessment of the effect of food on the PK of GRT7041 following single-dosing

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  31. Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] [SAD] for fed and fasted state

    Assessment of the effect of food on the PK of GRT7041 following single-dosing

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  32. Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) [SAD] for fed and fasted state

    Assessment of the effect of food on the PK of GRT7041 following single-dosing

    Time frame: Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)

  33. Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] of midazolam

    PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1/2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days, and when administered alone and after single day and 14 days of treatment with GRT7041

    Time frame: Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)

  34. Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) of midazolam

    PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1/2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days, and when administered alone and after single day and 14 days of treatment with GRT7041

    Time frame: Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)

  35. Maximum Observed Plasma Concentration (Cmax) of midazolam

    PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1/2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days, and when administered alone and after single day and 14 days of treatment with GRT7041

    Time frame: Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)

  36. Time to Reach Maximum Observed Plasma Concentration (Tmax) of midazolam

    PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1/2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days

    Time frame: Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)

  37. Terminal Elimination Half-Life (t₁/₂) of midazolam

    PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1/2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days

    Time frame: Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.

Data sharing details ↗ · www.grunenthal.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 7 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 17, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Aug 24, 2026
CompletionEst.
Aug 28, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07289776
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Jan 14, 2026
Primary completion
Aug 24, 2026 (estimated)
Completion
Aug 28, 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Grünenthal Clinical Trial Helpdesk
Contact
clinical-trials@grunenthal.com
+49 241 569 ext. 3223
Director Clinical Trials
Contact
clinical-trials@grunenthal.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion